Boehringer's COPD spray Combivent Respimat gets FDA approval

10/9/2011 | Family Practice News · Medscape (free registration)

The FDA approved Combivent Respimat Inhalation Spray, Boehringer Ingelheim's treatment for patients with chronic obstructive pulmonary disease. The therapy comprises albuterol sulfate and ipratropium bromide. It is a "suitable alternative" to chlorofluorocarbon-based Combivent inhalation aerosol, which will be phased out after Dec. 31, 2013, according to an FDA statement.

View Full Article in:

Family Practice News · Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
Winston-Salem, NC
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Director, Payer Marketing
Avalere Health
Washington, DC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX